The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the bio-clinical effects of sacubitril/valsartan
combination in treatment of patients with Congestive heart failure. Moreover, the
investigators aim to evaluate side effects of this combination.
- The following parameters were determined at baseline and at end of the study at 6 months of
the beginning.
1. New York Heart Association (NYHA) Class.
2. Frequency of hospitalization by acute exacerbation of CHF
3. NT-ProBNP
4. Left ventricular systolic function by Echocardiography
Moreover, the side effects of the drugs used during study was assessed by
1. Renal function (Serum creatinine) was performed every month till the end of the study.
2. Serum electrolytes (Potassium and Sodium) was performed every month till the end of the
study.
Phase:
Phase 4
Details
Lead Sponsor:
Amir Safwat
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan